Wednesday, September 29, 2021 8:19:24 AM
https://sec.report/Document/0001721868-21-000220/
Joshua Bauman - --- September 14, 2021 - --- $137,500
https://sec.report/Document/0001721868-20-000600/#f2sgrst8k112920ex10_09.htm
2.2 Conversion Price.
(a) Calculation of Conversion Price. The Conversion Price shall be, at the option of the Holder, (i) $0.001 (the “Fixed Conversion Price”) (subject to adjustment as further described herein) or (ii) 80% (the “Conversion Price Discount”) multiplied by the price per share paid by the investors in a subsequent Equity Financing (as defined herein) of the Borrower, provided, however, that after 6 months, the Conversion Price shall be equal to the lowest of: (1) the Fixed Conversion Price, (2) 60% multiplied by the lowest trade price of the Common Stock during the twenty one (21) consecutive Trading Day period immediately preceding the Trading Day that the Company receives a Notice of Conversion, and (3) a discount to market based on subsequent financings with other investors. For the avoidance of doubt, an “Equity Financing” shall mean the Borrower’s sale of its Common Stock or any securities conferring the right to purchase the Borrower’s Common Stock or securities convertible into, or exchangeable for (with or without additional consideration), the Borrower’s Common Stock.
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM